S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:BCRX

BioCryst Pharmaceuticals News Headlines

$13.78
-0.20 (-1.43%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$13.36
$14.01
50-Day Range
$11.18
$16.69
52-Week Range
$8.37
$18.48
Volume
4.47 million shs
Average Volume
6.32 million shs
Market Capitalization
$2.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.49
Get BioCryst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

BioCryst Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BCRX
News Sentiment

0.70

0.40

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BCRX Articles
This Week

1

3

BCRX Articles
Average Week



BioCryst Pharmaceuticals (NASDAQ:BCRX) News Headlines Today

SourceHeadline
finance.yahoo.com logoAre Institutions Heavily Invested In BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shares?
finance.yahoo.com - January 14 at 6:06 PM
insidertrades.com logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) CEO Jon P. Stonehouse Sells 184,000 Shares
insidertrades.com - January 13 at 6:48 PM
fool.com logoWhy BioCryst Pharmaceuticals Stock Is Skyrocketing This Week
fool.com - January 13 at 4:57 PM
MarketBeat logoBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 12.7%
americanbankingnews.com - January 12 at 12:48 PM
msn.com logoBioCryst Is On Fire: What Do Options Traders Expect Next?
msn.com - January 12 at 10:32 AM
nasdaq.com logoBiocryst Pharmaceuticals Inc. Shares Close the Day 11.2% Higher - Daily Wrap
nasdaq.com - January 12 at 1:53 AM
MarketBeat logoBioCryst Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:BCRX)
americanbankingnews.com - January 11 at 6:32 PM
finance.yahoo.com logoBioCryst Stock at $21 a Share? This Analyst Thinks It’s Possible
finance.yahoo.com - January 11 at 3:52 PM
MarketBeat logoBioCryst Pharmaceuticals (NASDAQ:BCRX) Receives "Buy" Rating from HC Wainwright
americanbankingnews.com - January 11 at 1:36 PM
MarketBeat logoBioCryst Pharmaceuticals (NASDAQ:BCRX) Sees Strong Trading Volume
americanbankingnews.com - January 11 at 12:20 PM
finance.yahoo.com logoWhy BioCryst Pharmaceuticals Stock Is Jumping on Monday
finance.yahoo.com - January 10 at 2:55 PM
MarketBeat logoBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up to $11.56
americanbankingnews.com - January 10 at 11:38 AM
seekingalpha.com logoBioCryst sees Q4 Orladeyo revenue of $45.6M
seekingalpha.com - January 10 at 9:55 AM
finance.yahoo.com logoBioCryst Announces Preliminary Full Year 2021 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2022 ORLADEYO Net Revenue and Peak Sales Guidance
finance.yahoo.com - January 10 at 9:55 AM
nasdaq.com logoSwelling losses haven't held back gains for BioCryst Pharmaceuticals (NASDAQ:BCRX) shareholders since they're up 85% over 5 years
nasdaq.com - January 9 at 9:07 AM
seekingalpha.com logoBioCryst begins patient enrollment in REDEEM-1 trial of BCX9930 for rare blood disorder
seekingalpha.com - January 7 at 1:21 PM
finance.yahoo.com logoBioCryst Begins Patient Enrollment in REDEEM-1 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
finance.yahoo.com - January 7 at 1:21 PM
finance.yahoo.com logoBioCryst to Present at 40th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 10:09 AM
finance.yahoo.com logoThere’s an Opportunity Brewing in BioCryst Stock, Says Analyst
finance.yahoo.com - December 15 at 1:56 PM
finance.yahoo.com logoBioCryst (BCRX) Begins Enrollment in PNH Study on BCX9930
finance.yahoo.com - November 30 at 2:15 PM
finance.yahoo.com logoInsider Buying: The BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Senior VP & CFO Just Bought 60% More Shares
finance.yahoo.com - November 30 at 9:14 AM
finance.yahoo.com logoBioCryst Begins Patient Enrollment in REDEEM-2 Pivotal Trial Evaluating BCX9930 as Oral Monotherapy for Patients with PNH
finance.yahoo.com - November 29 at 9:08 AM
nasdaq.com logoInsider Buying: The BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Just Bought 75% More Shares
nasdaq.com - November 26 at 1:06 AM
benzinga.com logoThinking about buying stock in Innoviz Technologies, Avaya Holdings, BioCryst Pharmaceuticals, Lithium Americas Corp, or FuelCell Energy?
benzinga.com - November 23 at 9:54 AM
finance.yahoo.com logoBioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
finance.yahoo.com - November 22 at 8:14 AM
finance.yahoo.com logoBioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
finance.yahoo.com - November 22 at 8:14 AM
finance.yahoo.com logoRoyalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals
finance.yahoo.com - November 22 at 8:14 AM
finance.yahoo.com logoBioCryst: Orladeyo on Track to Reach Top of the HAE Market
finance.yahoo.com - November 5 at 7:41 AM
finance.yahoo.com logoBioCryst Presents New Data Showing Sustained Reduction of HAE Attack Rates and Improved Patient Satisfaction After Patients Switch to ORLADEYO® (berotralstat)
finance.yahoo.com - November 5 at 7:41 AM
nasdaq.com logoBioCryst Pharmaceuticals Becomes Oversold (BCRX)
nasdaq.com - November 4 at 4:30 PM
nasdaq.com logoInsiders are probably glad they sold their shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) after 17% drop
nasdaq.com - November 4 at 9:14 AM
nasdaq.com logoBCRX Makes Notable Cross Below Critical Moving Average
nasdaq.com - November 3 at 6:12 PM
finance.yahoo.com logoBioCryst Pharmaceuticals (BCRX) Q3 2021 Earnings Call Transcript
finance.yahoo.com - November 3 at 6:12 PM
fool.com logoHere's Why BioCryst Pharmaceuticals Stock Is Losing Ground Today
fool.com - November 3 at 1:34 PM
finance.yahoo.com logoBioCryst Reports Third Quarter 2021 Financial Results and Upcoming Key Milestones
finance.yahoo.com - November 3 at 8:11 AM
finance.yahoo.com logoBioCryst Appoints Jinky Ang Rosselli Chief Data and Insights Officer
finance.yahoo.com - November 1 at 11:05 AM
finance.yahoo.com logoBioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
finance.yahoo.com - October 26 at 8:56 AM
finance.yahoo.com logoDo Hedge Funds Love BioCryst Pharmaceuticals, Inc. (BCRX)?
finance.yahoo.com - October 25 at 8:21 PM
finance.yahoo.com logoBioCryst to Report Third Quarter 2021 Financial Results on November 3
finance.yahoo.com - October 20 at 10:32 AM
finance.yahoo.com logo2 Super-Charged Growth Stocks to Buy Now
finance.yahoo.com - October 13 at 10:35 AM
nasdaq.com logoFirst Week of November 19th Options Trading For BioCryst Pharmaceuticals (BCRX)
nasdaq.com - October 6 at 1:57 PM
finance.yahoo.com logo3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better
finance.yahoo.com - September 30 at 8:07 AM
finance.yahoo.com logoBCRX Oct 2021 12.000 put
finance.yahoo.com - September 29 at 4:45 PM
finance.yahoo.com logoBioCryst to Present at 2021 Cantor Virtual Healthcare Conference
finance.yahoo.com - September 21 at 9:30 AM
finance.yahoo.com logoBioCryst Appoints Dr. Amy McKee to Board of Directors
finance.yahoo.com - September 20 at 8:20 AM
finance.yahoo.com logoNICE Recommends BioCryst's Hereditary Angioedema Med
finance.yahoo.com - September 16 at 5:52 PM
nasdaq.com logoU.K's NICE Recommends BioCryst's Orladeyo To Prevent Attacks In HAE Patients
nasdaq.com - September 16 at 1:37 AM
finance.yahoo.com logoNICE Recommends BioCryst’s ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
finance.yahoo.com - September 15 at 8:36 PM
nasdaq.com logoFirst Week of BCRX January 2024 Options Trading
nasdaq.com - September 14 at 8:56 PM
finance.yahoo.com logoBioCryst Announces Approval of ORLADEYO® (berotralstat) in United Arab Emirates
finance.yahoo.com - September 9 at 9:35 AM
Get BioCryst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.